Barinthus Biotherapeutics plc - American Depositary Shares BRNS 深 滬
等待開盤 01-03 09:30:00 美东时间
0.72
+0.020
+2.84%
華盛通- 最 高0.7389
- 今 開0.729
- 成交量 2.00万股
- 最 低 0.7193
- 昨 收 0.7001
- 總市值 2904.44万
- 52周最高 2.92
- 市盈率 靜 --
- 換手率 0.05%
- 52周最低 0.64
- 委 比 90.48%
- 總股本 4033.94万
- 歷史最高 17.99
- 量 比 0.45
- 振 幅 2.80%
- 歷史最低 0.64
- 每 手 1
- 風險率 0.25%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Barinthus Bio Issues Update On First-In-Human Phase 1 Trial Of VTP-1000 In Adults With Celiac Disease
VTP-1000, an antigen-specific immunotherapy to treat celiac disease, showed a dose-dependent pharmacological effect in the SAD portion of the trialVTP-1000 was well-tolerated with no treatment-related SAEsThe MAD portion
2025-12-10 21:01
美股大行评级 | Stifel上调特斯拉目标价升至508美元；多家大行上调Vita Coco目标价最高至58美元
今日重点评级关注：HC Wainwright & Co.：维持Oncolytics Biotech"买入"评级，目标价从5美元升至10美元；HC Wainwright & Co.：维持Barinthus Biotherapeutics"买入"评级，目标价从3美元升至4美元
2025-11-18 15:28
HC Wainwright & Co. Maintains Buy on Barinthus Biotherapeutics, Raises Price Target to $4
HC Wainwright & Co. analyst Yi Chen maintains Barinthus Biotherapeutics (NASDAQ:BRNS) with a Buy and raises the price target from $3 to $4.
2025-11-17 20:29
ChemDiv To Continue R&D Support As Clywedog Merges With Barinthus Therapeutics; Combined Entity To Trade Under Ticker CLYD On Nasdaq
ChemDiv, a global provider of integrated drug discovery solutions, today announced that it will continue providing chemistry, computational, and clinical pharmacology support to Clywedog Therapeutics as the company
2025-10-24 23:05
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of Shareholders
NEW YORK, Oct. 16, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or...
2025-10-17 11:58
Barinthus Biotherapeutics And Clywedog Therapeutics Enters Into A Definitive All-Stock Merger Agreement To Form Combined Company; Before Transaction Closes The Combined Company May Initiate Partial Tender Offer To Purchase Up To $27M Worth Of Its Outstanding Shares Held By Barinthus Bio Shareholders
Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio"), an immunology and inflammation company focused on developing therapies that promote immune tolerance, and Clywedog Therapeutics, Inc. ("Clywedog"), a private
2025-09-30 20:18
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Equillium (NASDAQ:EQ) shares moved upwards by 98.9% to $0.98 during Mo...
2025-08-12 01:06
Barinthus Biotherapeutics GAAP EPS of -$0.52
Barinthus Biotherapeutics press release (NASDAQ:BRNS): Q2 GAAP EPS of -$0.52. As of June 30, 2025, cash, cash equivalents and restricted cash was $87.8 million, compared to $100.6 million as of March ...
2025-08-07 23:13
Barinthus Biotherapeutics Q2 EPS $(0.52) Misses $(0.33) Estimate
Barinthus Biotherapeutics (NASDAQ:BRNS) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.33) by 57.58 percent. This is a 20.93 percent decrease over losses of $(0.43) per
2025-08-07 20:12
Barinthus Biotherapeutics Q1 EPS $(0.49) Misses $(0.36) Estimate
Barinthus Biotherapeutics (NASDAQ:BRNS) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.36) by 36.11 percent. This is a 22.5 percent decrease over losses of $(0.40) per
2025-05-07 21:20
